Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo

Cornelia Fischera Large Molecule Research, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Michael W. Munksb Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, USAView further author information

Ann B. Hillb Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, USAView further author information

Richard A. Kroczekc Molecular Immunology, Robert-Koch-Institute, Berlin, GermanyView further author information

Stefan Bissingerd Discovery Oncology, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Verena Brandd Discovery Oncology, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Martina Schmittnaegeld Discovery Oncology, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Sabine Imhof-Junga Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany

Eike Hoffmanna Large Molecule Research, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Frank Hertingd Discovery Oncology, Roche Innovation Center Munich, Penzberg, GermanyView further author information

Christian Kleine Discovery Oncology, Roche Innovation Center Zurich, Zurich, Switzerland

Hendrik Knoetgenf Therapeutic Modalities, Roche Innovation Center Basel, Basel, SwitzerlandCorrespondence[email protected]
View further author information

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.